• Foundation and Funding
  • International Affairs
  • PR and Marketing
  • Infrastructure
  • Biosamples and (Pre)clinic
  • Network
  • » 05.01.2017 Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
    Founded in Freising (near Munich), co-located in Boston (USA), NASDAQ-listed Pieris joins forces in immuno-oncology drug development with Servier Pharma (France). » more
  • » 05.12.2016 Recent developments in personalized medicine
    On November 29 and 30, 230 experts from all over Europe participated in the 6th Munich Biomarker Conference in Munich. The international conference on personalized medicine was organized by BioM, the network agency of Bavaria‚Äôs biotechnology industry. Interdisciplinary exchange and dialogue between researchers, physicians, and industry had been... » more
  • » 15.10.2016 Strong immuno start in Munich: iOmx hits the ground running
    Immuno-oncology startup iOmx Therapeutics has raised 40 million Euro in its first round of financing. » more
  • » 29.09.2016 Medigene (Munich) launches a billion-dollar collaboration with bluebird bio
    "We are delighted to collaborate with bluebird bio, a leader in the field of cell and gene therapy, including cancer immunotherapy," said Dolores J. Schendel. » more
  • » 10.09.2016 Rigontec: 15 million euros for a new immunotherapy RNA-technology
    The Munich-based firm also starts to gain a foothold in the American market by setting up a new company in the US (Boston). » more
  • » 17.05.2016 Horst Domdey in Nature Outlook: Research Commercialization
    Munich Biotech Cluster and lessons learned in 20 years of support for entrepreneurship in biopharma. » more